000070741 001__ 70741 000070741 005__ 20190709135502.0 000070741 0247_ $$2doi$$a10.1089/AID.2016.0323 000070741 0248_ $$2sideral$$a99580 000070741 037__ $$aART-2017-99580 000070741 041__ $$aeng 000070741 100__ $$aTreviño, Ana 000070741 245__ $$aHTLV infection in HCV-antibody positive patients in Spain. 000070741 260__ $$c2017 000070741 5060_ $$aAccess copy available to the general public$$fUnrestricted 000070741 5203_ $$aSince hepatitis C virus (HCV) and human T-lymphotropic virus (HTLV) share transmission routes, dual infection could be frequent. In Spain, HTLV underdiagnosis is highlighted by the high proportion of patients presenting either with tropical spastic paraparesis or adult T cell leukemia at first diagnosis. We examined whether the renewed efforts for expanding HCV testing may provide a sentinel population that might selectively be targeted to unveil asymptomatic HTLV carriers. The presence of anti-HTLV antibodies was examined in 3,838 consecutive individuals with reactive HCV serology attended during the last 3 years at 13 hospitals distributed across the Spanish geography. Overall 71% were male, and the median age was 41 years old. Foreigners represented 9% of the study population. A total of 50 individuals (1.3%) were seroreactive for HTLV, being 30 confirmed as HTLV-2 and 2 as HTLV-1 (0.12%). The remaining 18 had indeterminate Western blot patterns. Most individuals with HTLV-2 and HTLV indeterminate serology were human immunodeficiency virus positive, former injection drug users, and native Spaniards. In contrast, the two HTLV-1 infections were found in men coming from Brazil and the Dominican Republic, respectively. In summary, the overall prevalence of HTLV infection in individuals living in Spain seropositive for HCV is 1.3%, more than 10-fold greater than in general outclinics in Spain. However, immigrants from HTLV-1 endemic regions and former injection drug users with HTLV-2 infection are by far the major contributory groups in HCV patients. Therefore, testing for HTLV in newly diagnosed HCV individuals would not contribute much to improve late HTLV diagnosis in Spain. 000070741 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000070741 590__ $$a1.935$$b2017 000070741 591__ $$aINFECTIOUS DISEASES$$b64 / 88 = 0.727$$c2017$$dQ3$$eT3 000070741 591__ $$aVIROLOGY$$b26 / 35 = 0.743$$c2017$$dQ3$$eT3 000070741 591__ $$aIMMUNOLOGY$$b128 / 155 = 0.826$$c2017$$dQ4$$eT3 000070741 592__ $$a1.066$$b2017 000070741 593__ $$aImmunology$$c2017$$dQ2 000070741 593__ $$aVirology$$c2017$$dQ2 000070741 593__ $$aInfectious Diseases$$c2017$$dQ2 000070741 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000070741 700__ $$aAguilera, Antonio 000070741 700__ $$aRodríguez-Iglesias, Manuel. 000070741 700__ $$aHernandez, Ana 000070741 700__ $$0(orcid)0000-0001-5134-1006$$aBenito, Rafael$$uUniversidad de Zaragoza 000070741 700__ $$aRoc, Lourdes 000070741 700__ $$aRamos, José Manuel 000070741 700__ $$aOrtíz de Lejarazu, Raul 000070741 700__ $$aRodríguez, Carmen 000070741 700__ $$aRomero, Jorge del 000070741 700__ $$aCalderon, Enrique 000070741 700__ $$aGarcía Costa Juan 000070741 700__ $$aPoveda, Eva 000070741 700__ $$aRequena, Silvia 000070741 700__ $$aSoriano, Vicente 000070741 700__ $$aMendoza, Carmen de 000070741 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología 000070741 773__ $$g54, A (2017), 150-164$$pAIDS res. hum. retrovir.$$tAIDS RESEARCH AND HUMAN RETROVIRUSES$$x0889-2229 000070741 8564_ $$s158526$$uhttps://zaguan.unizar.es/record/70741/files/texto_completo.pdf$$yPostprint 000070741 8564_ $$s73612$$uhttps://zaguan.unizar.es/record/70741/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000070741 909CO $$ooai:zaguan.unizar.es:70741$$particulos$$pdriver 000070741 951__ $$a2019-07-09-11:47:16 000070741 980__ $$aARTICLE